<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682939</url>
  </required_header>
  <id_info>
    <org_study_id>17.0177</org_study_id>
    <nct_id>NCT03682939</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population</brief_title>
  <acronym>ProPositive</acronym>
  <official_title>Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the immunogenicity, safety and tolerability of co-administration
      of vaccinations for meningitis B (Bexsero®) and meningitis ACWY (Menveo®) in adults and
      children aged 10-45 years living with HIV. All participants will be vaccinated with both
      Menveo® and Bexsero® on days 0 and 30. Immunogenicity will be determined on venous blood
      sampled at days 0 and 60. Adverse effects will be recorded to evaluate safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hSBA geometric mean titres to relevant strains of meningococcal B following two doses of the 4CmenB vaccine (Bexsero®) in people living with HIV</measure>
    <time_frame>Day 0 (baseline) and Day 60</time_frame>
    <description>The human complement serum bactericidal assay (hSBA) mean titres against relevant strains of meningococcal B at baseline and one month after completion of vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants who achieve at least a four fold increase in hSBA titres.</measure>
    <time_frame>Day 60</time_frame>
    <description>Blood will be taken one month after the second vaccine and serum tested for hSBA titres. The proportion of participants who achieve at least a four fold increase in hSBA titres will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants who achieve a 'protective' hSBA titre of &gt;1:4 after two doses of Bexsero</measure>
    <time_frame>Day 60</time_frame>
    <description>Blood will be taken one month after the second vaccine and serum tested for hSBA titres. The proportion of participants who are deemed to have protective titres &gt;1:4 will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of solicited and unsolicited adverse and serious adverse events after two doses of MenACWY (Menveo®) and 4CMenB (Bexsero®) vaccines when co-administered in people living with HIV</measure>
    <time_frame>Day 7 after vaccines 1 and 2</time_frame>
    <description>We will assess the following:
The incidence of subjects with solicited local and systemic AEs up to 7 days (including the day of vaccination) after Visits 1 and 2.
The incidence of subjects with any other (unsolicited) AEs, including any SAEs, AEs leading to withdrawal and medically attended AEs up to 7 days (including the day of vaccination) after Visits 1 and 2.
The incidence of subjects with SAEs and AEs leading to withdrawal throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean titres to Meningococcal ACWY antigens after two doses of the MenACWY (Menveo®) vaccine in people with HIV at one month after the second vaccination</measure>
    <time_frame>Day 60</time_frame>
    <description>We will measure rSBA GMTs for MenACWY antigens at baseline and Visit3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least a four fold change in rSBA from baseline to 30 days after the second vaccine</measure>
    <time_frame>Day 0 and Day 60</time_frame>
    <description>The proportion of subjects with at least 4 fold increase in rSBA against relevant MenACWY serogroups from baseline to Visit3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with &quot;protective&quot; rSBA titres &gt;1:8 against relevant MenACWY serogroups after two doses of Menveo</measure>
    <time_frame>Day 60</time_frame>
    <description>The proportion of subjects with &quot;protective&quot; rSBA titres &gt;1:8 against relevant MenACWY serogroups at Visit3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hiv</condition>
  <condition>Meningitis, Meningococcal</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bexsero® (meningitis B vaccine)</intervention_name>
    <description>Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menveo® (meningitis ACWY vaccine)</intervention_name>
    <description>Menveo® 0.5ml IM vaccine administered into dominant arm of participant</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any 10-45-year old male or female patients with confirmed HIV infection where they (or
             someone with parental responsibility) can sign fully informed consent and are able to
             comply with study requirements.

        Exclusion Criteria:

          -  Pregnancy or breast feeding,

          -  History of MenACWY (Menveo® or Nimenrix®) and 4CMenB (Bexsero®) vaccination in the
             previous 2 years,

          -  Receipt of other non-live vaccines within 2 weeks and live vaccines within 4 weeks of
             first dose, planned receipt of vaccine within 2 weeks of study visits,

          -  Current active malignancy,

          -  Known latex allergy

          -  Known or suspected hypersensitivity to any components of the vaccines or history of
             severe allergic reaction after previous vaccination

          -  Bleeding disorder preventing IM vaccination,

          -  Any acute or chronic illness which according to the investigators judgement would
             prevent patients to receive the vaccines or participate in the study

          -  Participation in clinical trials concerning investigational medical product within 0
             days or before completion of the study

          -  Children in care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Cosgrove, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Cosgrove, MBBS PhD MRCP</last_name>
    <phone>+44(0)2087252316</phone>
    <email>ccosgrov@sgul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Isitt, MBChB MRCP</last_name>
    <phone>+44(0)2087252316</phone>
    <email>cisitt@sgul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Georges University Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catheirne E Isitt, MBChB</last_name>
      <phone>02087252316</phone>
      <email>vaccine@sgul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Simmons RD, Kirwan P, Beebeejaun K, Riordan A, Borrow R, Ramsay ME, Delpech V, Lattimore S, Ladhani S. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med. 2015 Dec 9;13:297. doi: 10.1186/s12916-015-0538-6.</citation>
    <PMID>26654248</PMID>
  </reference>
  <reference>
    <citation>Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015 Mar;15(3):2. doi: 10.1007/s11910-015-0524-6. Review.</citation>
    <PMID>25637287</PMID>
  </reference>
  <reference>
    <citation>Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, Steiner-Sichel L, Ngai S, Shepard C, Weiss D. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014 Jan 7;160(1):30-7. doi: 10.7326/0003-4819-160-1-201401070-00731.</citation>
    <PMID>24166695</PMID>
  </reference>
  <reference>
    <citation>Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, Meiring S, Govender N, von Gottberg A; Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA). Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS. 2010 Jun 1;24(9):1351-60. doi: 10.1097/QAD.0b013e32833a2520.</citation>
    <PMID>20559040</PMID>
  </reference>
  <reference>
    <citation>Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.</citation>
    <PMID>23515099</PMID>
  </reference>
  <reference>
    <citation>Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, Cruz AC, Pereira-Manfro W, de Oliveira RH, Abreu TF, Hofer CB. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. Pediatr Infect Dis J. 2015 May;34(5):e113-8. doi: 10.1097/INF.0000000000000630.</citation>
    <PMID>25876102</PMID>
  </reference>
  <reference>
    <citation>Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.</citation>
    <PMID>22622049</PMID>
  </reference>
  <reference>
    <citation>Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015 Jun 26;33(29):3322-30. doi: 10.1016/j.vaccine.2015.05.027. Epub 2015 May 27.</citation>
    <PMID>26025807</PMID>
  </reference>
  <reference>
    <citation>Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.</citation>
    <PMID>22260988</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>HIV</keyword>
  <keyword>meningitis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Bexsero</keyword>
  <keyword>Menveo</keyword>
  <keyword>co-administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

